Core Insights - The company reported a total revenue of 2.398 billion yuan for Q3 2025, with a net profit attributable to shareholders of 260 million yuan and a net cash inflow from operating activities of 590 million yuan [1]. Financial Performance - The latest debt-to-asset ratio stands at 27.37%, ranking 70th among disclosed peers, which is an increase of 2.58 percentage points from the previous quarter and 0.71 percentage points from the same period last year [2]. - The company's gross profit margin is 53.35%, ranking 54th among peers, with a return on equity (ROE) of 5.52% [2]. - The diluted earnings per share (EPS) is 1.28 yuan [2]. - The total asset turnover ratio is 0.37 times, while the inventory turnover ratio is 1.71 times [2]. Shareholder Structure - The number of shareholders is 17,200, with the top ten shareholders holding a total of 135 million shares, accounting for 64.60% of the total share capital [2]. - The largest shareholder is Changsha Medical Investment Co., Ltd. with a holding of 40.7% [2].
可孚医疗(301087.SZ)：2025年三季报净利润为2.60亿元